Northland Capital Markets Maintains Outperform Rating for PolarityTE: Here's What You Need To Know

Northland Capital Markets has decided to maintain its Outperform rating of PolarityTE PTE and lower its price target from $1.25 to $1.00.

Shares of PolarityTE are trading down 4.11% over the last 24 hours, at $0.70 per share.

A move to $1.00 would account for a 42.86% increase from the current share price.

About PolarityTE

PolarityTE Inc is a commercial-stage biotechnology and regenerative biomaterials company. It's focused on transforming the lives of patients by discovering, designing and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement or regeneration of skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.